[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
July 2006

A Randomized, Placebo-Controlled, Double-blind Trial Comparing Narrowband UV-B Plus 0.1% Tacrolimus Ointment With Narrowband UV-B Plus Placebo in the Treatment of Generalized Vitiligo

Arch Dermatol. 2006;142(7):927-947. doi:10.1001/archderm.142.7.927

Narrowband UV-B (NB UV-B) therapy has recently been shown to be effective in the repigmentation of patients with vitiligo, without significant adverse effects. In recent uncontrolled studies, topical tacrolimus therapy has also been reported to cause repigmentation of vitiligo lesions, particularly on the face and neck. To explore the possibility of synergism between these 2 modalities, we conducted a prospective, randomized, controlled trial of therapy with NB UV-B and tacrolimus or placebo for patients with generalized vitiligo.

First Page Preview View Large
First page PDF preview
First page PDF preview